Table 1.
Current active trials in HNSCC with novel single agentsa
| Trial Number | Trial phase | Drug | Pathway targeted | Molecular selection | Setting | Status |
|---|---|---|---|---|---|---|
| NCT02429089 | 1 | LEE011 | Cell cycle | No | Recurrent, metastatic | Recruiting |
| NCT02264678 | 1, 2 | AZD6738 | DNA repair | No | Recurrent, metastatic, in combination with chemotherapy or MEDI4736 or olaparib | Recruiting |
| NCT02567396 | 1 | Talazoparib | DNA repair | No | Recurrent, metastatic | Not yet recruiting |
| NCT01711541 | 1, 2 | Veliparib | DNA repair | No | Recurrent, metastatic, in combination with chemotherapy | |
| NCT02365662 | 1 | ABBV-221 | EGFR | No | Recurrent, metastatic | Recruiting |
| NCT01345669 | 3 | Afatinib | ERBB | No | Placebo controlled post-chemoradiotherapy | Recruiting |
| NCT01415674 | 2 | Afatinib | ERBB | No | Neoadjuvant | Active, not recruiting |
| NCT01427478 | 3 | Afatinib | ERBB | No | Placebo controlled randomised phase 3, maintenance therapy after post-operative chemoradiotherapy | Recruiting |
| NCT02131155 | 3 | Afatinib | ERBB | No | Placebo controlled adjuvant trial | Recruiting |
| NCT02216916 | 2 | HM781-36B | ERBB | No | Recurrent, metastatic | Recruiting |
| NCT02145312 | 2 | BYL719 | PI3K | No | Recurrent, metaststic | Not yet recruiting |
| NCT02540928 | 2a | AMG319 | PI3K | HPV-negative | Placebo controlled neoadjuvant therapy | Recruiting |
aClinical trials with immune checkpoint inhibitors are not included in this Table